Physician profile
Michael S Davis
NPI 1225031693
$11,880.43
in general payments reported to CMS, 2019-2025
33 companies · $1,143 in 2025
The $1,143 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,796 · 2020: $1,779 · 2021: $1,914 · 2022: $1,593 · 2023: $1,723 · 2024: $1,933 · 2025: $1,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,049 · Consulting Fee: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,048.78 |
| Consulting Fee | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,734.04 | 2019-2025 | Ofev |
| Glaxosmithkline, LLC. | $1,512.88 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,215.28 | 2019-2025 | Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $881.46 | 2021-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $823.06 | 2019-2025 | Opsumit, Uptravi |
| Philips North America LLC | $682.74 | 2019-2024 | (8874) Incourage |
| Grifols USA, LLC | $603.57 | 2019-2024 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $600.00 | 2024-2025 | |
| Genzyme Corporation | $520.76 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $477.99 | 2020-2024 | Hyqvia, Glassia |
| Mayne Pharma Commercial LLC | $424.42 | 2020-2022 | |
| Advanced Respiratory, INC | $372.40 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $365.66 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $251.65 | 2022-2023 | Quviviq |
| Mylan Specialty L.P. | $251.31 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $201.21 | 2024-2025 | |
| Baxter Healthcare | $175.12 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Fisher & Paykel Healthcare INC | $123.86 | 2020-2024 | Fisher & Paykel Healthcare |
| Merck Sharp & Dohme LLC | $123.55 | 2019-2024 | Winrevair |
| Genentech USA, INC. | $94.26 | 2019 | |
| Paratek Pharmaceuticals, INC. | $76.11 | 2024 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $61.52 | 2019 | |
| Shire North American Group INC | $47.52 | 2019 | |
| Csl Behring | $44.81 | 2019-2023 | Hizentra |
| Electromed, INC. | $43.31 | 2022-2023 | Smartvest |
| Axsome Therapeutics, INC. | $33.40 | 2024 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $26.48 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.00 | 2021 | |
| Johnson & Johnson Health Care Systems INC. | $21.17 | 2023 | Opsumit |
| Vapotherm INC | $19.97 | 2021 | |
| Vifor Pharma, INC. | $18.46 | 2024 | Zemaira |
| Ceribell, INC. | $14.24 | 2020 | |
| Hospira, INC. | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.